Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Kimmelman

Showing results (41-50 of 192) with videos related to

Pageof 20
Sort By:
Journal of Medical Ethics|October 15, 2015
Assessing risk/benefit for trials using preclinical evidence: a proposalJonathan Kimmelman, Valerie Henderson
Nature Medicine|July 5, 2019
Ethical development of stem-cell-based interventionsAmanda MacPherson, Jonathan Kimmelman
Cancer Research|May 19, 2007
Faithful companions: a proposal for neurooncology trials in pet dogsJonathan Kimmelman, Josephine Nalbantoglu
Nature Biotechnology|June 9, 2012
Should preclinical studies be registered?Jonathan Kimmelman, James A Anderson
Clinical Trials (London, England)|March 29, 2022
Practical steps to identifying the research risk of pragmatic trialsScott Yh Kim, Jonathan Kimmelman
Science (New York, N.Y.)|April 25, 2020
Against pandemic research exceptionalismAlex John London, Jonathan Kimmelman
Perspectives in Biology and Medicine|January 8, 2021
Introduction to the Special Issue on the <i>Belmont Report</i>Franklin G Miller, Jonathan Kimmelman
Elife|November 25, 2015
Why clinical translation cannot succeed without failureAlex John London, Jonathan Kimmelman
Plos Medicine|March 23, 2011
Predicting harms and benefits in translational trials: ethics, evidence, and uncertaintyJonathan Kimmelman, Alex John London
Lancet (London, England)|July 8, 2008
Justice in translation: from bench to bedside in the developing worldAlex John London, Jonathan Kimmelman
Pageof 20

Showing results (41-50 of 192) with videos related to

Sort By:
Pageof 20
Journal of Medical Ethics|October 15, 2015
Assessing risk/benefit for trials using preclinical evidence: a proposalJonathan Kimmelman, Valerie Henderson
Nature Medicine|July 5, 2019
Ethical development of stem-cell-based interventionsAmanda MacPherson, Jonathan Kimmelman
Cancer Research|May 19, 2007
Faithful companions: a proposal for neurooncology trials in pet dogsJonathan Kimmelman, Josephine Nalbantoglu
Nature Biotechnology|June 9, 2012
Should preclinical studies be registered?Jonathan Kimmelman, James A Anderson
Clinical Trials (London, England)|March 29, 2022
Practical steps to identifying the research risk of pragmatic trialsScott Yh Kim, Jonathan Kimmelman
Science (New York, N.Y.)|April 25, 2020
Against pandemic research exceptionalismAlex John London, Jonathan Kimmelman
Perspectives in Biology and Medicine|January 8, 2021
Introduction to the Special Issue on the <i>Belmont Report</i>Franklin G Miller, Jonathan Kimmelman
Elife|November 25, 2015
Why clinical translation cannot succeed without failureAlex John London, Jonathan Kimmelman
Plos Medicine|March 23, 2011
Predicting harms and benefits in translational trials: ethics, evidence, and uncertaintyJonathan Kimmelman, Alex John London
Lancet (London, England)|July 8, 2008
Justice in translation: from bench to bedside in the developing worldAlex John London, Jonathan Kimmelman
Pageof 20